MedTrace Logo

GSK706769 Repeat Dose Study

NCT00711386 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-08-03

No results posted yet for this study

Summary

To determine safety, tolerability and Pharmacokinetics of GSK706769

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK706769

50mg, 100mg, 200mg, or 400mg

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-16
Primary Completion
2008-09-12
Completion
2008-09-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00711386 on ClinicalTrials.gov